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OBJECTIVE: The effects of acute continuous positive airway pressure therapy on left ventricular diastolic
function and functional capacity in patients with compensated systolic heart failure remain unclear.
METHODS: This randomized, double-blind, placebo-controlled clinical trial included 43 patients with heart
failure and a left ventricular ejection fraction ,0.50 who were in functional classes I-III according to the New
York Heart Association criteria. Twenty-three patients were assigned to continuous positive airway pressure
therapy (10 cmH2O), while 20 patients received placebo with null pressure for 30 minutes. All patients
underwent a 6-minute walk test (6MWT) and Doppler echocardiography before and immediately after
intervention. Clinicaltrials.gov: NCT01088854.
RESULTS: The groups had similar clinical and echocardiographic baseline variables. Variation in the diastolic
function index (e9) after intervention was associated with differences in the distance walked in both groups.
However, in the continuous positive airway pressure group, this difference was greater (continuous positive
airway pressure group: D6MWT=9.44+16.056De9, p = 0.002; sham group: D6MWT=7.49+5.386De9; p = 0.015).
There was a statistically significant interaction between e9 index variation and continuous positive airway
pressure for the improvement of functional capacity (p = 0.020).
CONCLUSIONS: Continuous positive airway pressure does not acurately change the echocardiographic indexes
of left ventricle systolic or diastolic function in patients with compensated systolic heart failure. However,
30-minute continuous positive airway pressure therapy appears to have an effect on left ventricular diastolic
function by increasing functional capacity.
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& INTRODUCTION
Noninvasive ventilation with continuous positive airway
pressure (CPAP) has been described as a non-pharmacolo-
gical approach in patients with compensated systolic heart
failure (HF). Previous studies suggested that the benefits of
CPAP included improved oxygenation, reduced myocardial
oxygen demand, decreased respiratory work and decreased
left ventricular (LV) preload and afterload (1-4). However,
the effects of CPAP on the LV systolic function indexes of
HF patients are controversial. The increases in left ventricular
ejection fraction (LVEF) and cardiac output have been
shown to persist for over 1 hour of rest following a single
session of noninvasive therapy (bilevel positive airway
pressure) (5). However, other authors did not observe any
CPAP-related changes in these indexes, regardless of
whether the evaluation was performed during or after the
intervention (6,7).
Notably, most of the studies evaluating the hemodynamic
effects of CPAP in HF patients included subjects with
obstructive sleep apnea. Therefore, it is difficult to establish
whether the cardiac improvement is associated with the
apnea treatment or is due to a direct effect on the heart (8).
Patients with compensated HF and reduced LVEF present
decreased functional capacity related to increased LV
diastolic filling pressure rather than a decrease in the
ejection fraction itself. Diastolic dysfunction causes dyspnea,
which is the most important limiting symptom and can be
used as a predictor of major outcomes such as decom-
pensated HF and death (9,10).
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The effects of CPAP on myocardial oxygenation
and metabolic demand may increase diastolic function by
improving relaxation. Therefore, it is reasonable to hypothe-
size that the CPAP-induced increase in diastolic function
indexes would have a beneficial effect on functional
capacity in patients with compensated systolic HF.
Thus, the aim of this study was to investigate the acute
effects of first-time CPAP application on LV diastolic
function and its influence on functional capacity in
asymptomatic HF patients with reduced LVEF.
& METHODS
Study Population
Informed consent was provided by each patient before
study participation, and the protocol was approved by the
Institutional Committee of Research Ethics (OF.405/2009-
CEP).
The study was a prospective, unicenter, randomized,
double-blind trial. Recruitment began in January 2008 and
ended in January 2010, and 43 consecutive patients with
compensated HF and reduced ejection fraction were
enrolled from the outpatient clinics of our hospital.
The inclusion criteria were as follows: men and women
who were previously diagnosed with systolic HF; NYHA
functional class I-III; LVEF,0.50; receiving optimal phar-
macological treatment (11,12); and a stable clinical condi-
tion, as shown by the absence of dyspnea exacerbation for at
least 3 months and the ability to cooperate with the
procedures.
The exclusion criteria included unstable angina or acute
coronary syndrome in the last 6 months, arterial blood
pressure.140/90 mmHg, atrial fibrillation, complex ven-
tricular arrhythmia, chronic obstructive pulmonary disease,
obstructive sleep apnea, more than mild cardiac valve
disease, active infection, or physical impairment that would
cause a walking limitation.
This study was registered at ClinicalTrials.gov
(NCT01088854).
Study Protocol
All patients underwent baseline 2-dimensional and
Doppler echocardiographic examinations and were rando-
mized using a random-figure computerized program in a
proportion of 1:1. Twenty patients were included in the
sham group (simulated CPAP), and 23 patients were
included in the CPAP group. The patients, the echocardio-
grapher, and the physiotherapist who conducted the 6MWT
were blinded to the randomization.
After clinical evaluation, the patients underwent echo-
cardiography followed by the initial 6MWT in an indoor 30-
meter-long corridor according to the American Thoracic
Society guidelines (13). In addition to the walked distance,
the heart rate, respiratory rate, pulse oximetry, blood
pressure, and modified Borg Scale score were recorded
before and after the test. All patients had already experi-
enced at least one 6MWT in the last month; therefore, they
were already familiar with the procedure. At the conclusion
of the initial 6MWT, patients allocated to the CPAP group
were positioned comfortably for the CPAP procedure with
10 cmH2O positive pressure for 30 minutes. Subsequently,
the CPAP was withdrawn, and a second echocardiogram
was performed. Patients allocated to the sham group
underwent the same procedure except for the null pressure.
Because the patients had never experienced this interven-
tion, we assumed that they were unaware of whether
they were receiving CPAP. Finally, a second 6MWT was
performed by the same therapist who was blinded to the
CPAP procedure.
Echocardiography
Standard transthoracic echocardiograms were performed
by the same examiner (SGZB) using an HDI 5000 SONOCT
ultrasound (Phillips, Andover, MA, USA) according to
American Society of Echocardiography and Canadian
Consensus recommendations (14,15). In our laboratory, the
intra-observer variability is below 5%. Left atrial (LA) and
LVEF volumes were obtained using Simpson’s rule. The
LVEF was calculated as the normalized difference between
the diastolic and systolic volumes. Spectral Doppler record-
ings from the mitral valve as well as the Doppler velocities
of the septal and lateral annular tissue were obtained from
the apical 4-chamber view. Peak early (E wave) and late
(A wave) transmitral flow velocities, E/A ratio, isovolu-
metric relaxation time (IRT), and deceleration time (DTE)
were measured. Longitudinal systolic (Sm), early diastolic
(e9), and late diastolic (a9) mitral annular velocities were
measured, and average velocities were calculated from
three consecutive cardiac cycles.
Statistical Analysis
Summary data are expressed as the mean¡standard
deviation. Etiology, comorbidity, and medication frequen-
cies were compared between groups using the chi-square
(x2) test or Fisher’s exact test. Student’s t test was used for
other comparisons between groups either before or after
intervention. Linear regression analysis was used to assess
the association between changes in walked distance and
variations in diastolic index (e9) immediately after CPAP. A
general linear model was used to analyze the interaction
between e9 index variation and CPAP to improve functional
capacity. A 2-tailed significance level of p,0.05 was
considered statistically significant, with a power equal to
80%. All analyses were performed using the commercially
available statistical package SAS for Windows, version 9.2
(Cary, NC, USA).
& RESULTS
Despite the overt heart failure, all patients were oligo-
symptomatic. A total of 151 of the 195 patients who were
observed in the outpatient clinics of our hospital from
January 2008 to January 2010 presented with one or more of
the exclusion criteria; therefore, 44 patients (27 men and 17
women) were included in the study protocol. Of these
patients, 20 were randomly assigned to the sham group,
while 23 were assigned to the CPAP group.
Table 1 shows the anthropometric and cardiac morpho-
metric data before CPAP intervention. There were no
differences between the groups.
The etiologies of cardiomyopathy were ischemia, arterial
hypertension, alcoholism, and Chagas disease. HF induced
by chemotherapy was observed in one patient in the sham
group. The comorbidities were current smoking, hypothyr-
oidism, hyperlipidemia, diabetes mellitus, and arterial
hypertension. The two groups had similar causes of HF
and comorbidities. Also, there were no differences between
the groups as medications were concerned (Table 2).
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The parameters recorded in the first and second 6MWT
were similar between the groups. Before CPAP, the mean
distances walked by patients in the sham and CPAP groups
were 451¡55.8 meters and 437¡70.7 meters, respectively
(p = 0.480). After the intervention, patients in the sham
group walked 452¡62 meters, while those in the CPAP
group walked 443¡67.7 meters (p = 0.656). Table 3 shows
the echocardiography data. There was no difference
between the groups before or after CPAP.
Before- and after-intervention differences in ventricular
function analyzed using linear regression indicated a
statistically significant association between e9 index varia-
tion and walked distance variation in the CPAP group
(Figure 1). That is, for each centimeter increase in annular
mitral diastolic velocity, there was a mean increase of 16.05
meters in the 6MWT (D6MWT = 9.44+16.056De9; R = 0.61;
p = 0.002). This association, although statistically significant
in the sham group, had less of an influence on physical
capacity (D6MWT = 7.49+5.386De9; R = 0.53; p = 0.015).
Furthermore, there was a statistically significant interaction
between e9 index variation and CPAP for the improvement
of functional capacity (p = 0.020). There was no association
between the systolic function indexes and 6MWT in either
group.
& DISCUSSION
The present study revealed the acute effects of 30-minute
CPAP application in patients with compensated HF and
systolic ventricular dysfunction through the randomization
of patients with similar baseline characteristics.
Echocardiograms revealed cardiac enlargement in all
individuals as well as myocardial hypertrophy and reduced
ejection fraction. These results establish that the studied
sample showed significantly impaired left ventricular
function although they showed no signs of congestion.
After the intervention, there was no difference between
the groups with respect to the variables obtained during
the 6MWT. These results differ from those described by
Chermont et al. (16) and Lima et al. (17). These authors
evaluated the effects of 30-minute CPAP treatment in 12
patients with HF in a randomized study. The CPAP group
showed increases in the distance covered and peak heart
rate. Improved exercise tolerance was also found in a
study by Steiner et al. (18), who examined a series of
11 patients with compensated HF without sleep apnea
(only 6 patients completed the study). Overnight 6-hour
CPAP applications were performed every night for
approximately 8 months. Cardiopulmonary exercise test-
ing showed improved peak oxygen consumption, exercise
duration, and workload. However, in these studies,
fewer patients were included and the protocols used were
distinctly different from ours. Bradley et al. (4) conducted
a study that included 258 HF patients who were randomly
assigned to receive nocturnal CPAP or no treatment for 2
months. CPAP was associated with improved physical
capacity in the 6MWT.
In the present study, the lack of improved exercise
capacity after CPAP could be explained by the short-term
administration; however, other researchers obtained similar
results even with more prolonged use (6,7,19). Therefore, it
is reasonable to state that the question of whether CPAP
actually exerts effects on exercise tolerance in patients with
compensated systolic HF must be definitively answered
before more in-depth studies can be performed.
No significant changes in LV systolic function were
observed in either group in the current study. In the
normal heart, the initiation of CPAP therapy acutely
increases intrathoracic pressure and decreases venous
return and LV filling, resulting in decreased cardiac output
(3,20). However, studies have shown that the simultaneous
reduction of preload (caused by decreased filling pressure)
and afterload (due to decreased transmural pressure)
would improve systolic function in patients with HF
(3,20-22).
Despite the potential beneficial effects of CPAP on systolic
function, the literature examining this issue is contradictory.
Table 1 - Baseline anthropometric and morphometric
characteristics of the patients.
Sham group
(n=20)
CPAP group
(n=23) p
Sex (men/women) 13/7 13/10 0.490
Age (years) 55.0¡11.11 54.3¡9.66 0.827
BMI (kg/m2) 25.7¡5.07 26.7¡4.95 0.512
LVM (g) 280¡56.7 260¡78.4 0.123
LAV (mL/m2) 53.81¡15.19 54.7¡16.80 0.854
LVDd (cm) 6.4¡0.67 6.4¡1.01 0.764
LVDs (cm) 5.2¡0.77 5.2¡1.10 0.868
IVSd (cm) 1.00¡0.144 0.96¡0.145 0.275
PWd (cm) 0.99¡0.112 0.94¡0.106 0.105
Values are presented as the mean¡SD. BMI: body mass index; IVSd:
interventricular septum diameter at end-diastole; LAV: left atrial volume;
LVDd: left ventricular end-diastolic dimension; LVDs: left ventricular
systolic dimension; LVM: left ventricular mass; PWd: posterior wall
diameter at end-diastole.
Table 2 - Etiologies and comorbidities.
Sham group
(n=20)
CPAP group
(n=23) p*
Etiology
Ischemic 6 5
Hypertensive 5 7
Idiopathic 2 5
Alcoholism 1 1
Chagas disease 5 5
Chemotherapy 1 0
0.534
Comorbidities
Hypertension 11 15
Current smoking 7 2
Hypothyroidism 1 1
Hyperlipidemia 5 6
Diabetes mellitus 6 9
0.220
Medications
Diuretics 16 22
ACE/BRA 18 23
Beta-blockers 15 23
Spirolactone 11 14
Digoxin 12 12
Aspirin 7 11
Statin 6 7
Warfarin 3 1
0.927
ACE: Angiotensin-converting enzyme; ARB: angiotensin II receptor
blocker.
*Chi-square test.
CPAP and diastolic function
Bussoni MF et al.
CLINICS 2014;69(5):354-359
356
Few studies have found improved hemodynamics in HF
patients after the acute use of continuous or bilevel positive
airway pressure (3,5,16,22). Long-term CPAP therapy has
also been found to increase ejection fraction and cardiac
output (4,23,24). Yoshinaga et al. (2) and Johnson et al. (20)
compared the two application periods and observed
improved ejection fraction and stroke volume only after
chronic therapy.
On the contrary, in a randomized placebo-controlled trial
performed by Smith et al. (6), no difference was found in
ejection fraction after 6 weeks of nocturnal auto-titrating
CPAP.
Interestingly, most patients in these studies presented
with obstructive sleep apnea in addition to chronic HF,
which would influence the effect of long-term CPAP on
cardiac function and exercise tolerance. For example, Sin
et al. (8) described an improvement in LVEF after 3 months
of nightly CPAP only in HF patients with Cheyne-Stokes
respiration and central sleep apnea. CPAP had no sig-
nificant effect on LVEF in patients without these respiratory
conditions.
There is a paucity of data on the effects of CPAP on LV
diastolic function, despite its major impact on the symptoms
and prognosis of patients with HF. Johnson et al. (20)
investigated the effects of acute and long-term CPAP
therapy on LV systole and diastole. In that study, 7 patients
with HF and obstructive sleep apnea who used CPAP were
compared with 5 patients with HF without obstructive sleep
apnea who were not using CPAP. Only chronic CPAP
therapy improved systolic function, and diastolic function
was not affected by either chronic or acute CPAP use.
Conversely, we previously described a series of 11
patients with compensated HF who received acute CPAP
therapy. Echocardiograms were performed at baseline and
30 minutes later while the patients were still actively
receiving CPAP. CPAP therapy did not alter LV systolic
function but did significantly improve diastolic function
(25).
In the present study, LV diastolic function indices were
evaluated at baseline and after CPAP withdrawal, and we
found that the use of CPAP had no benefit. Despite this
apparent lack of effect, our findings regarding the associa-
tion between intervention-related variations in the diastolic
function index (e9) and the walked distance were interest-
ing. In both groups, improved diastolic function was
associated with a proportional improvement in physical
performance. This result was expected because it is well
Table 3 - Systolic and diastolic function indices before and after intervention.
Pre-intervention Post-intervention
Indexes Sham group (n=20) CPAP group (n =23) p* Sham group (n=20) CPAP group (n =23) p*
LVEF 0.36¡0.07 0.37¡0.09 0.551 0.38¡0.07 0.39¡0.09 0.477
CO (L/min) 3.56¡0.52 3.62¡0.42 0.662 3.59¡0,50 3.65¡0.46 0.680
SV (mL) 51.5¡9.5 53¡9.5 0.647 52.7¡9.6 54.5¡10.3 0.567
E 69¡28.5 81¡24.5 0.162 73¡28.6 81¡20.0 0.291
A 70¡21.9 69¡25.5 0.820 68¡21.5 69¡25.5 0.863
E/A (cm/s) 1.19¡0.87 1.51¡1.06 0.286 1.27¡0.82 1.45¡0.92 0.498
DTE (ms) 241¡81.2 205¡65.2 0.117 231¡84.6 208¡60.8 0.306
IRT (ms) 123¡27.6 108¡25.4 0.061 124¡31.8 111¡24.8 0.135
s9 (cm/s) 7.5¡1.1 7.6¡1.4 0.359 7.5¡1.0 7.9¡1.3 0.834
e9 (cm/s) 9.8¡1.7 10.5¡1.7 0.211 9.3¡1.7 10.3¡1.6 0.075
a9 (cm/s) 11.8¡2.4 12.9¡2.5 0.682 12.7¡2.1 13.0¡2.7 0.652
E/e9 7.22¡3.35 7.86¡2.65 0.491 7.91¡2.96 8.11¡2.48 0.815
Data are expressed as the mean¡SD. A: peak late transmitral flow velocity; a9: peak late diastolic mitral annular velocity (average of lateral and septal
sites); CO: cardiac output; DTE: deceleration time of E; E: peak early transmitral flow velocity; e9: peak early diastolic mitral annular velocity (average of
lateral and septal sites); IRT: isovolumetric relaxation time; LVEF: left ventricular ejection fraction (Simpson’s rule); s9: peak systolic mitral annular velocity
(average of lateral and septal sites); SV: stroke volume.
*Student’s t test.
Figure 1 - Association between the variations in the diastolic
function index (e9) induced by CPAP (panel A) or by sham
treatment (panel B) and the variation in walked distance.
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known that diastolic function influences exercise capacity
(26-28). However, whereas in the sham group, variations in
the e9 index were associated with an increase of only 5.38
meters in walked distance, in the CPAP group, each
increment in the e9 index was associated with a mean
increase of 16.05 meters in walked distance. This result
indicated an interaction between e9 index variation
and CPAP for the improvement of functional capacity.
Therefore, in a general sense, although acute CPAP therapy
did not affect ventricular function, it may cause an
incremental increase in functional capacity in those patients
who respond to acute CPAP with improved diastolic
function. Our results also indicate that the effect of CPAP
may involve factors other than ventricular function, includ-
ing, for instance, pulmonary gas exchange, which was not
analyzed in this study.
The main limitation of our study was the small number of
included patients, which prevented the demonstration of
further effects of CPAP on diastolic function indexes.
Despite this limitation, our data raised an important
question about the relevance of LV diastolic function in
the functional capacity of patients with compensated
systolic HF as well as the beneficial effect of CPAP.
Further studies are needed to confirm these results.
CPAP does not acutely alter echocardiographic indexes of
LV systolic or diastolic function in patients with compen-
sated systolic HF. However, 30-minute CPAP therapy
appears to influence LV diastolic function by increasing
functional capacity.
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